Last reviewed · How we verify
AP09004
AP09004 is a drug that targets the dopamine receptor D2.
AP09004 is a drug that targets the dopamine receptor D2. Used for Parkinson's disease.
At a glance
| Generic name | AP09004 |
|---|---|
| Sponsor | Intec Pharma Ltd. |
| Drug class | Dopamine receptor antagonist |
| Target | D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to the D2 receptor, which is involved in the regulation of movement and other functions. This can help to alleviate symptoms of certain neurological disorders.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AP09004 CI brief — competitive landscape report
- AP09004 updates RSS · CI watch RSS
- Intec Pharma Ltd. portfolio CI